We investigated the potential of TIF1γ as a novel therapeutic strategy to ameliorate DM‐related complications in the kidneys and muscles of db/db mice, a model of type 2 DM (T2DM)–induced CKD. Here, TRIM33 is linked to diabetes mellitus.